Scientific Partners
Russell Dushin
Russell Dushin
Russell Dushin
Education:
Ph.D. Cornell University
Experience:
- 1991-2018 American Cyanamid/Wyeth/Pfizer
Medicinal Chemistry
Expertise:
- HTS Triage
- Lead Optimization
- Natural products synthesis and derivatization
- Macrocycles
- Antibody-drug conjugates
- DNA-Encoded library chemistry
- Over 70 patents and publications
Contact
russell.dushin@thamespharmapartners.com
LinkedIn:
Gwen Fate
Russell Dushin
Russell Dushin
Education:
Ph.D. University of Chicago
Experience:
- 1992-2016 Pfizer/Parke-Davis Pharmacokinetics and Drug Metabolism
- 2016-2019 Consultant in ADME sciences for drug discovery and pre-IND planning
Expertise:
- Drug design to modulate metabolic and PK profile
- Biologics development pre-IND to registration
- Project filing strategies
- Regulatory doc's and FDA queries
- Scientific writing
Contact:
g.fate@thamespharmapartners.com
LinkedIn:
Bruce Lefker
Russell Dushin
Bruce Lefker
Education:
Ph.D. Colorado State University
Experience:
- 1988-2018 Pfizer Medicinal Chemistry
- 2016-2017 Head of Medicinal Chemistry, Weizmann Institute
Expertise:
- Project strategy and leadership
- Building discovery organizations
- Lead generation
- Candidate identification
- Cheminformatics
- Technology assessment and implementation
- Over 90 publications and patents
Contact:
bruce.lefker@thamespharmapartners.com
LinkedIn:
David Perry
Ralph Robinson
Bruce Lefker
Education:
Ph.D. University of Cambridge, UK
Experience:
1983-2018
- Pfizer Veterinary Medicine
- Natural Products Discovery
- Medicinal Chemistry
- Inventor of Revolution®/Stronghold®.
Expertise:
- Outsourcing leadership and project management
- Drug design and optimization
- Synthesis
- Natural product chemistry and structure elucidation
- Stable isotope incorporation
- Scientific writing
- Over 50 patents and publications
Contact:
david.a.perry@thamespharmapartners.com
LinkedIn:
Ralph Robinson
Ralph Robinson
Ralph Robinson
Education:
Ph.D. Yale University
Experience:
- 1986-2018 Pfizer Medicinal Chemistry
- Led the multidisciplinary team that discovered the antidiabetes drug Steglatro.
- Synthesis group lead
Expertise:
- Drug design and optimization
- Synthesis
- Project strategy and leadership
- Prodrugs and antedrugs
- Covalent inhibitors
- Chemical biology probes
- Scientific writing
- Over 70 patents and publications.
Contact:
ralph.p.robinson@thamespharmapartners.com
LinkedIn:
Frank Lovering
Ralph Robinson
Ralph Robinson
.jpg/:/cr=t:0%25,l:0%25,w:100%25,h:91.91%25/rs=w:388,h:388,cg:true)
Education:
Ph.D. University of California, Irvine
Experience:
- 2010-2021 Pfizer Computational Chemistry (2018-2021 as Director)
- 1999-2007 Wyeth Medicinal chemistry and computational chemistry
- 1996-1999 Genetics Institute Medicinal Chemistry
Expertise:
- Drug design and optimization
- Computational chemistry
- Structure-based drug design
- Ligand-based design
- Homology modeling
- Chemoinformatics
- 12 patents and 31 publications.
Contact:
frank.lovering@thamespharmapartners.com
Rose Gonzales
Stephen Wright
Rose Gonzales
Education:
Ph.D. Georgia Institute of Technology
Experience:
Fellow, Society of Laboratory Automation and Screening
- 2021 - 2023 Group Lead, Pfizer Global Clinical Supply
- 2010 - 2021 Director, Pfizer Compound Management & Distribution
- 2007 - 2010 Director, Pfizer Discovery Analytical Chemistry
- 1999 - 2007 Associate Research Fellow, Pfizer Discovery Technologies
Expertise:
Recognized industry expert in sample management, automation technology with additional skills in HTS, assay development, project management, and clinical study supply logistics
Contact:
Mark Flanagan
Stephen Wright
Rose Gonzales
Education:
Ph.D. Colorado State University
Experience:
- 1997-2023 Pfizer Medicinal Chemistry
- Co-inventor of XELJANZ™ and CIBINQO™
- Synthesis group lead
Expertise:
- Drug design and optimization
- Outsourcing leadership and project management
- DNA-encoded library technology
- Protein degraders
- Covalent inhibitors
- Antibacterials
- Over 70 patents and publications
Contact:
Stephen Wright
Stephen Wright
Stephen Wright
Education:
Ph.D. Harvard University
Experience:
- 1992-2023 Pfizer Medicinal Chemistry
- 1988 – 1992 DuPont Merck
- Contributor to discovery of PAXLOVID®, Brepocitinib and Zimlovisertib
- Team lead for two Phase 2 candidates
Expertise:
- Drug design and optimization
- Lead generation and HTS triage
- Synthetic route design and development
- Process optimization and safety
- Crystallization and solid form analysis
- Isotopic labeling
- Drug safety risk mitigation
- 105 research publications and 21 patents
Contact:
stephen.wright @thamespharmapartners.com